China Jo-Jo Drugstores, Inc. (CJJD): Business Model Canvas [Dec-2025 Updated]

You're looking at a major strategic pivot, and honestly, it's a smart move for a company like China Jo-Jo Drugstores, Inc. (CJJD) after its early 2025 restructuring into Ridgetech, Inc. We're talking about shedding assets to focus purely on higher-volume, lower-margin pharmaceutical wholesale, which is a completely different game than their old online pharmacy hustle. To give you a sense of the scale, their wholesale drug sales alone jumped 42.1% to $47.00 million in FY2024, contributing significantly to the $154.54 million total revenue. This new blueprint swaps consumer-facing complexity for supply chain efficiency, but what does that mean for their long-term value proposition and cost structure? Dive into the full Business Model Canvas below to see exactly how this asset-light model is built for survival and growth in China's drug distribution landscape.

China Jo-Jo Drugstores, Inc. (CJJD) - Canvas Business Model: Key Partnerships

You're looking at the partnerships that define the new, asset-light structure for the company, now operating as Ridgetech, Inc. as of February 28, 2025. This shift fundamentally changed who the key players are.

Allright (Hangzhou) Internet Technology Co. Ltd. for Wholesale Integration

The cornerstone of the new wholesale focus was the acquisition of Allright (Hangzhou) Internet Technology Co. Ltd. This wasn't a cash deal; it was an equity exchange. China Jo-Jo Drugstores, Inc. agreed to issue 2,225,000 ordinary shares to complete this. Honestly, that issuance represented a significant stake, making up 38% of the issued and outstanding ordinary shares after the transaction closed in the first quarter of 2025.

This partnership brought in a fast-growing pharmaceutical wholesale operation, which is important when you look at the prior year's performance. For context, in fiscal year 2024, the wholesale business already grew by 42.1%, hitting $47.00 million in revenue, while the retail side was shrinking.

Oakview International Limited Following the Divestiture

The move to wholesale required shedding the retail business, which was sold to the former CEO and a director. As part of that divestiture transaction, which concluded around the same time as the Allright acquisition, there was a significant share surrender. Lei Liu and Li Qi, along with their affiliates, surrendered a total of 2,548,353 ordinary shares back to the company in exchange for the retail assets. The specific equity in Zhejiang Jiuxin Investment Management Co. Ltd. was transferred to Oakview International Limited as part of this strategic realignment.

Here's a quick look at the revenue context that drove this partnership structure, based on fiscal year 2024 results:

Pharmaceutical Manufacturers for Drug Supply Agreements

As a wholesale-focused entity, securing robust supply agreements with pharmaceutical manufacturers is mission-critical. These partnerships ensure inventory flow for the newly acquired Allright operations and any remaining distribution channels. While specific contract values aren't public, the scale of the wholesale business dictates substantial volume commitments.

The company relies on these agreements to support its core product flow, which historically included:

• Pharmaceutical products for distribution.
• Nutritional supplements inventory.
• Herbs used for Traditional Chinese Medicine (TCM).

Logistics and Third-Party Warehousing Providers

Transitioning to an asset-light wholesale model means relying heavily on third-party logistics (3PL) providers to manage inventory movement and storage efficiently. This reduces the need for company-owned physical infrastructure, which aligns with the new strategy.

The partnership structure for logistics must cover nationwide distribution, which is complex given the prior focus on Hangzhou City. Key operational requirements for these partners include:

• Temperature-controlled storage capacity.
• Compliance with PRC pharmaceutical distribution regulations.
• High-volume last-mile delivery capabilities.

E-commerce Platforms like Tmall and JD.com for Online Sales

Even post-restructuring, maintaining an online presence is key, though the retail segment was divested. The online pharmacy segment generated $31.86 million in revenue in fiscal year 2024. Any ongoing e-commerce partnerships, likely now managed under the wholesale or a smaller specialized entity, would focus on B2B distribution through major platforms.

To be fair, the search results don't detail specific 2025 agreements with Tmall or JD.com following the February 2025 restructuring. However, the historical reliance on online channels suggests these platforms remain vital for market access, even if the sales model shifts from direct-to-consumer retail to wholesale fulfillment to other online sellers.

Finance: draft 13-week cash view by Friday.

China Jo-Jo Drugstores, Inc. (CJJD) - Canvas Business Model: Key Activities

You're looking at the core engine of China Jo-Jo Drugstores, Inc. (CJJD) as it pivots hard into wholesale in 2025. The key activities reflect a massive strategic shift announced in February 2025 to become an asset-light, wholesale-focused entity, which involved selling off the retail drugstores.

Managing a large-scale pharmaceutical wholesale distribution network

This activity became the central focus following the strategic restructuring in the first quarter of 2025. The company acquired Allright (Hangzhou) Internet Technology Co. Ltd. to bolster this segment, with the acquired entity representing 38% of the post-transaction issued and outstanding ordinary shares via an equity exchange. Prior to this shift, the wholesale segment was already showing significant momentum.

Here's a look at the scale of the business segments based on the last reported full fiscal year results:

The company's total gross profit for that period was $31.11 million, with the gross margin falling to 20.1% from 23.0% the prior year.

Supply chain optimization and inventory management

For China Jo-Jo Drugstores, Inc., optimization centers on integrating the newly acquired wholesale operations while shedding the physical footprint of the retail stores. This move inherently optimizes asset utilization. Industry-wide, supply chain leaders are heavily investing in technology to manage complexity; for instance, 50% of supply chain organizations planned investments in AI and advanced analytics applications through 2024 to manage escalating geopolitical tensions and shifting regulations.

Key operational focus areas for this activity include:

• Integrating Allright's wholesale infrastructure.
• Streamlining inventory flow for the asset-light model.
• Improving efficiency to enhance profitability.

The company's total employee count was reported at 1,047 as of early 2025.

Operating the online pharmacy platform and e-commerce storefronts

This activity is significantly curtailed as the retail drugstore business, which included the online pharmacy component, was divested in the Q1 2025 restructuring in exchange for the surrender of 2,548,353 ordinary shares held by the CEO and a director. The last reported performance for this channel showed a revenue of $31.86 million in FY2024, representing a 1.6% decline.

Regulatory compliance for drug distribution in China

Operating in China's healthcare sector requires constant adherence to national and provincial drug distribution rules. A stated goal of the February 2025 restructuring was to enhance market compliance alongside operational efficiency. The company, which is a Cayman Islands exempted company, previously had to address listing compliance, having regained compliance with Nasdaq Minimum Bid Price Requirement in March 2024.

Compliance activities involve:

• Maintaining licenses for pharmaceutical wholesale operations.
• Adhering to PRC regulations for online drug sales channels.
• Fulfilling ongoing reporting requirements for its listing on NASDAQ.

The company's reported annual income for the period ending March 2025 was a loss of $-4,230 K, while EBITDA was $2 million.

China Jo-Jo Drugstores, Inc. (CJJD) - Canvas Business Model: Key Resources

You're looking at the core assets China Jo-Jo Drugstores, Inc. relies on to execute its strategy, especially after the major pivot announced in early 2025. These aren't just items on a balance sheet; they are the foundational elements enabling the shift to an asset-light, wholesale-focused model.

Wholesale drug distribution licenses and permits

The ability to operate as a wholesale distributor of pharmaceutical and other healthcare products in China is a non-negotiable key resource. China Jo-Jo Drugstores, Inc. maintains these licenses through its operating entities, such as Zhejiang Jiuxin Medicine Co., Ltd., which has been the vehicle for its wholesale operations since August 2011. Furthermore, the company is a provider of healthcare services, which implies holding necessary permits for operating retail drugstores and having licensed doctors on site for consultations.

The strategic restructuring completed in the first quarter of 2025 cemented the importance of these wholesale authorizations, as the company is now explicitly focused on this segment.

Allright's established wholesale customer base and network

A critical new resource acquired in Q1 2025 was Allright (Hangzhou) Internet Technology Co. Ltd. This acquisition was executed via an equity exchange for 2,225,000 ordinary shares, which represented 38% of the Company's issued and outstanding ordinary shares post-transactions. Allright brought a fast-growing pharmaceutical wholesale business, immediately bolstering China Jo-Jo Drugstores, Inc.'s network.

This network is now the engine for the company's growth focus. To give you a sense of the scale this resource supports, the legacy wholesale business alone saw revenue growth of 42.1% in fiscal year 2024, reaching $47.00 million.

• Acquisition of Allright completed in Q1 2025.
• Allright brought a fast-growing pharmaceutical wholesale operation.
• The combined wholesale segment is now the primary strategic focus.

Working capital, which was $20.15 million cash as of March 31, 2024

Liquidity is always a key resource, especially during a strategic transition. You must anchor to the last reported figure for cash on hand, which was $20.15 million as of March 31, 2024. This cash position provided the necessary buffer for operations.

Subsequent financing activities in mid-2024, such as the registered direct offerings totaling approximately $3.37 million in June 2024 and $2.74 million in May 2024, were explicitly earmarked for general corporate purposes and working capital. This shows a consistent need to replenish and maintain operational funds to support the asset-light model.

Intellectual property for the online pharmacy platform

The technology underpinning the online pharmacy platform remains a vital resource, even as the retail segment is divested. This platform allows China Jo-Jo Drugstores, Inc. to interact digitally with customers and manage online sales channels, including presence on major platforms like Tmall and JD.com. While the retail focus is diminishing, the digital infrastructure is essential for the online pharmacy operations that remain.

For context on the scale of the digital operation before the retail divestiture, the online pharmacy revenue for fiscal year 2024 was $31.86 million, a slight decline of 1.6% year-over-year.

Here's a quick look at how some of these key resource-related metrics stack up:

The intellectual property is the proprietary code and infrastructure supporting the online pharmacy, which generated $31.86 million in revenue in the last full fiscal year before the restructuring was finalized. Also, remember the company is a licensed distributor; those licenses are the gates to the wholesale market.

China Jo-Jo Drugstores, Inc. (CJJD) - Canvas Business Model: Value Propositions

You're looking at the core reasons customers choose China Jo-Jo Drugstores, Inc. over competitors right now. The value proposition centers on a mix of traditional distribution strength and digital reach, even as the company navigates profitability challenges.

Cost-efficient pharmaceutical supply via the wholesale model

The wholesale segment is a clear driver of recent top-line momentum. For the fiscal year 2024, the Drug Wholesale segment surged by 42.1%, bringing in $47.00 million in revenue. This growth suggests China Jo-Jo Drugstores, Inc. is effectively capturing market share through its distribution network, which is key to offering cost advantages. The overall trailing twelve months (TTM) Gross Margin stood at 20.24%. This margin reflects the blended profitability across all operations, including the lower-margin wholesale activity.

The wholesale operation's contribution to the overall business structure is significant:

• Wholesale Revenue Growth (FY2024): 42.1%
• Wholesale Revenue Contribution (FY2024): $47.00 million
• Overall Gross Margin (TTM): 20.24%

Broad access to both Western and Traditional Chinese Medicine (TCM) products

China Jo-Jo Drugstores, Inc. provides a comprehensive offering that caters to diverse patient needs within China. The company operates across distinct segments that ensure this breadth of product access. This dual focus is a core differentiator in the local market, blending modern pharmaceuticals with established TCM offerings.

The business segments China Jo-Jo Drugstores, Inc. uses to deliver this value include:

• Retail Drugstores
• Online Pharmacy
• Drug Wholesale
• Herb Farming

Asset-light structure designed for enhanced profitability

The strategy leans on an asset-light approach, evident in the relatively small employee base supporting substantial revenue generation. With 1,047 employees reported, the company aims for operational leverage. The goal is enhanced profitability, though recent figures show this is still a work in progress. The TTM Net Margin was reported at -3.8%, indicating that while the wholesale side drives volume, overall cost management is still under pressure to translate that volume into net income.

Here's a quick look at some key financial metrics that define the current operational reality:

Convenience of 24/7 online pharmacy access for consumers

The Online Pharmacy segment taps directly into the growing digital healthcare trend. While specific China Jo-Jo Drugstores, Inc. online sales figures aren't immediately available, the context is a rapidly expanding sector. Globally, the online pharmacy market was projected to reach $131.65 billion in revenue in 2025. Furthermore, about 13.07% of people globally were expected to use online pharmacies in 2025. China Jo-Jo Drugstores, Inc.'s digital channel provides the 24/7 convenience that modern consumers expect, complementing its physical footprint.

The digital value proposition is supported by:

• Inclusion of an 'Online Pharmacy' segment.
• Participation in a global market expected to hit $131.65 billion in 2025.

Finance: draft 13-week cash view by Friday.

China Jo-Jo Drugstores, Inc. (CJJD) - Canvas Business Model: Customer Relationships

China Jo-Jo Drugstores, Inc. is actively reshaping its customer interactions following the strategic restructuring announced in February 2025, which pivots the company toward an asset-light, wholesale-focused model. This shift means the nature of relationships is heavily weighted toward business-to-business interactions rather than direct consumer sales.

Automated and transactional relationships with wholesale buyers form the backbone of the new operational focus. The wholesale business, which generated $47.00 million in revenue for the fiscal year ended March 31, 2024, relies on efficient, high-volume distribution to trading companies throughout China. This segment is expected to see increased transactional automation to support the asset-light strategy moving forward.

For the online pharmacy customers, the relationship remains largely self-service. This channel sells drugs through established third-party platforms such as Alibaba's Tmall and JD.com. The online pharmacy segment recorded revenue of $31.86 million in the fiscal year ending March 31, 2024. Customer interaction here is driven by platform efficiency, not direct, personalized service from China Jo-Jo Drugstores, Inc. itself.

A dedicated sales team is now crucial for managing key wholesale accounts, which is a direct consequence of the strategic move to strengthen the wholesale business for greater profitability. While the retail business generated $75.68 million in FY2024, the future relationship management effort is concentrated on securing and maintaining high-value wholesale contracts. The company is managing relationships with suppliers and healthcare providers as a core risk factor, which directly impacts these wholesale customer ties.

Here's a look at the revenue composition from the last fully reported fiscal year, which sets the stage for the late 2025 wholesale emphasis:

The company's overall trailing 12-month revenue as of March 31, 2025, stood at $120M. The customer relationship structure is now defined by these distinct interaction models:

• Automated processing for routine wholesale orders.
• Platform-driven self-service for online pharmacy transactions.
• High-touch account management for strategic wholesale partners.
• The company operates one hundred and nine (109) store locations under the store brand "Jiuzhou Grand Pharmacy" in Hangzhou city as of September 16, 2021, though the retail segment was sold in Q1 2025.

The shift in focus means that the success of the dedicated sales team in securing volume from wholesale buyers is now a primary driver of the company's financial health, especially as the market cap was $40.2M as of November 12, 2025.

China Jo-Jo Drugstores, Inc. (CJJD) - Canvas Business Model: Channels

The Channels component for China Jo-Jo Drugstores, Inc. reflects a significant shift following the strategic restructuring completed in the first quarter of 2025, moving the primary focus to wholesale operations.

Wholesale distribution network across China

The wholesale distribution network is now the core channel following the divestiture of the retail business. This channel leverages the acquisition of Allright (Hangzhou) Internet Technology Co. Ltd. to enhance scalability in pharmaceutical distribution across China.

The last reported revenue for the wholesale business, prior to the full transition, was:

The wholesale segment's growth rate of 42.1% in Fiscal Year 2024 underscores the strategic direction China Jo-Jo Drugstores, Inc. is taking.

Online pharmacy platform (e.g., e-commerce storefronts)

The online pharmacy platform continues as a channel, though its revenue contribution has seen a slight recent contraction. This platform integrates with e-commerce marketplaces like Tmall and JD.com.

• Online Pharmacy Revenue (FY2024): $31,860,000.
• Year-over-year revenue change for Online Pharmacy (FY2024): -1.6%.
• The company previously operated with 109 store locations under the 'Jiuzhou Grand Pharmacy' brand before the retail business sale.

Direct sales force targeting independent drugstores and hospitals

This function is now intrinsically linked to the wholesale distribution channel, focusing on business-to-business sales rather than direct-to-consumer retail. The strategy emphasizes providing competitive prices to wholesale buyers.

The restructuring involved the surrender of 2,548,353 ordinary shares held by the former CEO and a director in exchange for the sale of the drug retail business. The acquisition of Allright Internet Technology, a pharmaceutical wholesale business, involved the issuance of 2,225,000 ordinary shares, representing 38% of issued and outstanding ordinary shares post-Transactions.

• The interim CEO, Frank Zhao, is tasked with overseeing the integration of Allright's business.
• The former CEO, Lei Liu, and director, Li Qi, resigned following the expected Q1 2025 closing of the restructuring transactions.

China Jo-Jo Drugstores, Inc. (CJJD) - Canvas Business Model: Customer Segments

You're looking at the customer base for China Jo-Jo Drugstores, Inc. (CJJD) right around late 2025, which means we have to factor in that major strategic shift announced in February 2025 to become a wholesale-focused entity. The customer base is definitely bifurcating based on the old structure versus the new intended structure.

Independent retail drugstores and pharmacy chains (primary wholesale focus)

This group forms the core of the new, asset-light focus. These are the entities buying in bulk from the company's contractually controlled affiliates. Based on the last fully reported segment data before the major restructuring, the wholesale business was showing significant strength. For fiscal year 2024, the wholesale business surged by 42.1%, reaching $47.00 million in revenue. This indicates that the wholesale segment is the primary target for growth and customer acquisition moving forward.

Hospitals and clinics requiring bulk pharmaceutical supplies

While a specific revenue line item for only hospitals and clinics isn't broken out separately from the wholesale segment in the latest public filings, they are implicitly included here as major recipients of bulk pharmaceutical supplies. The $47.00 million generated by the wholesale business in fiscal year 2024 represents the total volume supplied to professional entities like these, plus independent retail drugstores. This segment is now the strongest growth driver for China Jo-Jo Drugstores, Inc.

End-consumers purchasing Over-The-Counter (OTC) and prescription drugs online

This segment represents the former Online Pharmacy and Retail Drugstores businesses. The company announced the sale of its drug retail business in Q1 2025, meaning the direct-to-consumer retail customer base is largely being divested. For context on the scale before this, retail revenue (including pharmacies and medical clinics) was approximately 57.2% of total revenue for the fiscal year ended March 31, 2021, while online pharmacy revenue was 16.8%. The most recent full-year data shows retail drugstore revenue dipped 9.2% in fiscal year 2024 to $75.68 million, contrasting with the wholesale surge. The online consumer remains a segment, but its future structure post-divestiture is less clear from the wholesale-focused mandate.

Here's a quick look at the segment revenue performance from the last reported full fiscal year:

The customer segments are clearly shifting their weight:

• Wholesale segment growth rate: 42.1% in FY2024.
• Retail segment revenue decline: 9.2% in FY2024.
• Divestiture of retail business completed in Q1 2025.
• The company is transitioning to an asset-light, wholesale-focused model.
• The wholesale business is now the primary focus for customer engagement.

To be defintely clear, the customer base for China Jo-Jo Drugstores, Inc. as of late 2025 is overwhelmingly centered on B2B clients within the wholesale distribution channel, a direct result of the strategic restructuring.

China Jo-Jo Drugstores, Inc. (CJJD) - Canvas Business Model: Cost Structure

You're looking at the cost side of China Jo-Jo Drugstores, Inc.'s (CJJD) operations as of late 2025. Given the announced strategic shift in Q1 2025 to become an asset-light, wholesale-focused company, the cost profile is definitely in flux, moving away from the heavy fixed costs associated with its former retail footprint. Still, understanding the FY2024 baseline is key to seeing where the savings should materialize.

High Cost of Goods Sold (COGS) typical of a wholesale distributor is the primary cost driver here. Since the company is heavily pivoting toward wholesale-which saw revenue growth of 42.1% in FY2024 to reach $47.00 million-the cost of the products themselves dominates the expense structure. For the fiscal year ended March 31, 2024, the total revenue was $154.54 million, and the gross profit was $31.11 million. This means the approximate Cost of Goods Sold for FY2024 was around $123.43 million (Revenue minus Gross Profit). This high COGS percentage reflects the nature of a distributor business where margins are thinner compared to value-added services.

The gross margin itself compressed in FY2024, falling to 20.1% from a prior level of 23.0%. This margin pressure directly impacts the overall cost efficiency of the core product movement.

Logistics and distribution expenses for national coverage remain a significant, though perhaps more variable, cost. Even with the shift away from owned retail stores, maintaining a national wholesale distribution network across China requires substantial spending on warehousing, transportation, and last-mile delivery for B2B clients. These costs are embedded within operating expenses but are critical to supporting the wholesale segment's growth trajectory.

Selling, General, and Administrative (SG&A) expenses represent the overhead required to run the corporate structure, sales efforts, and administrative functions. For the fiscal year 2024, the reported SG&A expense was $34.643 million. This figure covers everything from executive salaries and office rent to marketing and compliance costs. The restructuring announced in early 2025, which involved the sale of the retail business and management changes, is specifically aimed at streamlining this SG&A base going into late 2025, especially by shedding retail-related overhead.

Technology maintenance for the online platform is another necessary, ongoing cost. China Jo-Jo Drugstores, Inc. operates an online pharmacy platform, which requires continuous investment in system upkeep, security, data compliance, and feature updates to compete with major e-commerce players like Tmall and JD.com. While a specific dollar amount for maintenance isn't readily available, it is a non-negotiable operational cost to support the $31.86 million in online pharmacy revenue generated in FY2024.

Here's a quick look at the key financial components that define the cost structure based on the most recent full fiscal year data:

The cost structure is characterized by these main outflows:

• High proportion of cost tied to product acquisition (COGS).
• Fixed and variable costs for national logistics network.
• Overhead from the corporate and sales structure (SG&A).
• Ongoing IT expenditure for e-commerce operations.

The strategic move to wholesale means the company is trying to trade higher absolute COGS for lower operating leverage costs, defintely. Finance: draft 13-week cash view by Friday.

China Jo-Jo Drugstores, Inc. (CJJD) - Canvas Business Model: Revenue Streams

You're looking at how China Jo-Jo Drugstores, Inc. (CJJD) actually brings in its money based on the latest full-year results. Honestly, the revenue picture for fiscal year 2024 shows a clear split in performance across the main segments.

The total top-line number for the fiscal year 2024 was $154.54 million. That's the starting point for any valuation work you're doing.

Here is the breakdown of how that $154.54 million was generated:

The wholesale side was definitely the star performer in FY2024. Drug Wholesale sales hit $47.00 million, marking a significant jump of 42.1% year-over-year. That growth is the result of focusing on competitive pricing and using modern wholesale platforms, as the Chairman noted.

The digital channel, Online Pharmacy sales, contributed $31.86 million in FY2024. To be fair, this segment saw a slight dip, down 1.6% from the prior year.

The core retail operations, which include the sales of nutritional supplements and healthcare products alongside prescription drugs, brought in $75.68 million. This segment experienced a year-on-year decrease of 9.2%.

When you look at the mix, you see where the operational focus is shifting:

• Drug Wholesale sales: $47.00 million.
• Online Pharmacy sales: $31.86 million.
• Retail Drugstore sales: $75.68 million.
• Sales of nutritional supplements and healthcare products are embedded within the retail figure.

The total revenue for FY2024 was $154.54 million, representing a 3.8% increase overall, driven almost entirely by the strength in the wholesale segment.

Finance: draft 13-week cash view by Friday.